{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Response to therapy was determined based on percentage of blasts in bone marrow, hematopoiesis, and requirement for supportive care (i.e., transfusions or cytokine growth factors). The modified International Working Group response criteria was used, based on Cheson, et al.","groups":[{"description":"Cycle 1- 5-azacytidine (Vidaza, AZA) 75mg/m2 IV/SC daily on days 1-7.\n\nSubsequent Cycles (cycles to be repeated every 28 days) AZA 75mg/m2 IV/SC daily on days 1-7.","id":"OG000","title":"5-azacytidine and Lintuzumab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"up to 5 years","title":"Complete Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}